Clovis Highlights Phase 1 Data from Studies of Targeted Radiotherapy

 

• First presentation of initial LuMIERE Phase 1 data demonstrated a manageable safety profile with preliminary evidence of activity

  • Nine patients treated to date with 177Lu-FAP-2286 up to 5.5 GBq/dose

  • No serious adverse events, treatment discontinuations, deaths or dose-limiting toxicity events related to 177Lu-FAP-2286 observed

  • Confirmed partial response in one patient who completed six administrations of 177Lu-FAP-2286 in the 3.7 GBq dose cohort

  • Recruitment of the 7.4 GBq dose cohort is ongoing

• FAP-2286 has shown high tumor uptake and prolonged retention across a range of solid tumors

• Data from a separate UCSF investigator-initiated Phase 1 imaging study of 68Ga-FAP-2286 in solid tumors will also be presented during the meeting

https://finance.yahoo.com/news/clovis-oncology-highlights-phase-1-180000773.html